Speaker(s): 

Hannah Krammes, MS, LGC, Genetic Counselor I, Geisinger (has nothing to disclose)

Jacqueline Mosher, BA, Patient-Participant and current Geisinger employee (has nothing to disclose)

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe the clinical implications of BRCA2 likely pathogenic/pathogenic variants and associated cancer risks.

• By the end of the session, participants will be able to identify and describe the common emotional responses experienced by MyCode patient-participants following the disclosure of actionable genetic results and explain the psychosocial factors that influence these responses.

• Participants will analyze case examples demonstrating coordinated, multidisciplinary care and will articulate the ways this approach improves patient engagement and clinical outcomes.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Adam Buchanan, MS, MPH, LCGC, Juliann Savatt, MS, LCGC, Melissa Kelly, MS, LCGC, Marc Williams, MD, and Cara McCormick, MPH have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose.

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None